scholarly journals Multiple vertebral fractures after suspension of denosumab. A series of 56 cases

Author(s):  
Manuel Sosa‐Henríquez ◽  
Oscar Torregrosa ◽  
Alejandro Déniz ◽  
Pedro Saavedra ◽  
Norberto Ortego ◽  
...  
2018 ◽  
Author(s):  
Paula Fernandez-Trujillo-Comenge ◽  
Agnieszka Kuzior ◽  
Manuel Esteban Nivelo-Rivadeneira ◽  
Ana Delia Santana-Suarez ◽  
Carmen Acosta-Calero ◽  
...  

Author(s):  
Liana Tripto-Shkolnik ◽  
Yair Liel ◽  
Naama Yekutiel ◽  
Inbal Goldshtein

AbstractDenosumab discontinuation is associated with rapid reversal of bone turnover suppression and with a considerable increase in fracture risk, including a risk for multiple vertebral fractures (MVF). Long-term follow-up of patients who sustained MVF after denosumab discontinuation has not been reported. This case-series was aimed to provide a long-term follow-up on the management and outcome of denosumab discontinuers who initially presented with multiple vertebral fractures. Denosumab discontinuers were identified from a computerized database of a large healthcare provider. Baseline and follow-up clinical, laboratory, and imaging data were obtained from the computerized database and electronic medical records. The post-denosumab discontinuers MVF patients consisted of 12 women aged 71±12. Osteoporotic fractures were prevalent before denosumab discontinuation in 6 of the patients. The majority received bisphosphonates before denosumab. MVF occurred 134±76 days after denosumab discontinuation. The patients were followed for a median of 36.5 (IQR 28.2, 42.5) months after MVF. Two patients passed-away. Two patients suffered recurrent vertebral fractures. Following MVF, patients were treated inconsistently with denosumab, teriparatide, oral, and intravenous bisphosphonates, in various sequences. Two patients underwent vertebroplasty/kyphoplasty. This long-term follow-up of real-world patients with MVF following denosumab discontinuation reveals that management is inconsistent, and recurrent fractures are not uncommon. It calls for clear management guidelines for patients with MVF after denosumab discontinuation and for special attention to this high-risk group.


2008 ◽  
Vol 57 (1) ◽  
pp. 10-12
Author(s):  
Osamu Kunigo ◽  
Kosei Ijiri ◽  
Takuya Yamamoto ◽  
Fumihiro Miyaguchi ◽  
Toshimi Nagatomo ◽  
...  

2019 ◽  
Vol 112 (11) ◽  
pp. 472-475 ◽  
Author(s):  
Manuel Sosa Henríquez ◽  
María Jesús Gómez de Tejada Romero ◽  
María Escudero-Socorro ◽  
Oscar Torregrosa Suau

Summary A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.


2020 ◽  
Vol 16 (6) ◽  
pp. 480-484
Author(s):  
Elisa Fernández Fernández ◽  
Diego Benavent Núñez ◽  
Gema Bonilla Hernán ◽  
Irene Monjo Henry ◽  
Sara García Carazo ◽  
...  

2007 ◽  
Vol 157 (15-16) ◽  
pp. 388-391
Author(s):  
Christian Muschitz ◽  
Paul Roschger ◽  
Janina Patsch ◽  
Isabella Pollhammer ◽  
Bruno Koller ◽  
...  

2016 ◽  
Vol 2 (3) ◽  
pp. 226-230
Author(s):  
Saša Magaš ◽  
Miroslav Ćaćić ◽  
Zrinka Sudar Magaš ◽  
Ivan Kruljac

Sign in / Sign up

Export Citation Format

Share Document